Challenges and Future Trends in Large Vessel Vasculitis
Authors:
- Kornelis S.M. van der GeestKGKornelis S.M. van der Geest
- Rosanne D. ReitsemaRRRosanne D. Reitsema
- Neeraj DhaunNDNeeraj Dhaun
- Taryn YoungsteinTYTaryn Youngstein
- Alexandre Wagner Silva de SouzaASAlexandre Wagner Silva de Souza
- Marc R. DweckMDMarc R. Dweck
- Ellen HendrikseEHEllen Hendrikse
- Andor W.J.M. GlaudemansAndor W.J.M. Glaudemans
- Elisabeth BrouwerEBElisabeth Brouwer
- 23 June 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 2064-2083
Abstract
Based on the Chapel Hill consensus criteria, the primary forms of vasculitis are classified by the predominant size of the affected blood vessels into large, medium, or small vessels. The two main forms of large vessel vasculitis (LVV) are giant cell arteritis and Takayasu arteritis, both of which are more prevalent in women while showing distinct geographic patterns of prevalence. The pathogenesis of LVV is complex and multifactorial, involving a combination of genetic predisposition, environmental and geographic triggers, immune dysregulation, and aging or (premature) senescence of the immune system and blood vessels. Diagnosis based on clinical presentation alone can be challenging because of the wide variety and often nonspecific symptoms that are associated with LVV. This has prompted the development of novel diagnostic tools to aid patient management, in particular advanced vascular imaging approaches. New therapies targeting specific immune pathways are now becoming available to improve outcomes while limiting the side effects associated with traditional glucocorticoid treatment. Advances in molecular imaging techniques may also enhance our ability to objectively monitor disease and treatment response in patients with LVV. Ongoing research aims to better understand the underlying mechanisms and to develop better targeted therapies for LVV, and to improve patient assessment and life time management. This narrative review will provide an in-depth update on current challenges and future trends in LVV, enhancing our understanding of its pathogenesis, diagnostic features, and management strategies, including disease- and treatment-related cardiovascular complications.Keywords
This publication has 99 references indexed in Scilit:
- Long-Term Outcomes and Prognostic Factors of Complications in Takayasu ArteritisCirculation, 2017
- Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patientsLaboratory Investigation, 2017
- Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2017
- A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell ArteritisThe American Journal of Human Genetics, 2017
- Relapses in Patients With Giant Cell ArteritisMedicine, 2014
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: Analysis of 204 Korean patients at a single centerInternational Journal of Cardiology, 2012
- Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritisRheumatology, 2008
- Coronary involvement in Takayasu's arteritisAutoimmunity Reviews, 2007
- Takayasu arteritis: a reviewJournal of Clinical Pathology, 2002